Breaking News Instant updates and real-time market news.

BSX

Boston Scientific

$42.15

0.28 (0.67%)

06:03
08/19/19
08/19
06:03
08/19/19
06:03

Boston Scientific acquisition of BTG expected to be immaterial to FY19 adj. EPS

Boston Scientific announced the completion of its acquisition of BTG pursuant to the previously announced scheme of arrangement. Upon the effectiveness of the scheme of arrangement, BTG became a wholly-owned subsidiary of Boston Scientific, and BTG shares no longer trade on the London Stock Exchange. Under the terms of the previously announced transaction, holders of BTG common shares will receive 840 pence in cash per share. Boston Scientific expects to complete the previously announced sale of its global embolic microspheres portfolio - comprised of Embozene, Embozene TANDEM and ONCOZENE brands - to Varian Medical Systems, Inc. in due course, a transaction entered into in connection with obtaining the antitrust clearances required to complete the BTG transaction. In addition, the company is initiating a process to explore the divestiture of the royalty stream associated with BTG's Zytiga licensing arrangements and anticipates closing this divestiture by the end of 2019. The transaction is expected to be immaterial to adjusted earnings per share in 2019 as a result of the BTG transaction closing later than originally anticipated, the divestiture of the Boston Scientific embolic microspheres portfolio, and the treatment of the licensing business as an asset for accounting purposes and its intended divestiture. The transaction is expected to be 4c-5c accretive in 2020 on an adjusted basis, and increasingly accretive thereafter. On a GAAP basis, the transaction is expected to be less accretive, or more dilutive as the case may be, due to amortization expense and acquisition-related net charges.

  • 04

    Sep

  • 09

    Sep

  • 13

    Nov

BSX Boston Scientific
$42.15

0.28 (0.67%)

06/27/19
STFL
06/27/19
NO CHANGE
Target $46
STFL
Buy
Boston Scientific price target raised to $46 after analyst day at Stifel
Stifel analyst Rick Wise said Boston Scientific hosted a "compelling" analyst day at which the company highlighted an "impressive array of sizable, recently-launched and future pipeline opportunities." The company's 2020-2022 targets are largely in-line with his and current consensus estimates and he senses this guidance is "highly achievable, if not conservative," Wise stated following the event. The analyst, who left his estimates largely unchanged but said he feels increasingly confident about his long-term projections, maintains a Buy rating on Boston Scientific with a price target of $46, up from $44 previously.
07/03/19
FBCO
07/03/19
NO CHANGE
Target $45
FBCO
Outperform
Sales of Boston Scientific's bead business not surprising, says Credit Suisse
Credit Suisse analyst Matt Miksic notes that Boston Scientific (BSX) has agreed to sell its portfolio of drug-loadable microspheres and "bland" embolic bead products for treating arteriovenous malformations and hyper vascular tumors to Varian (VAR) for $90M.The analyst does not view it as surprising, and reiterates an Outperform rating and $45 target on Boston Scientific's shares.
07/24/19
PIPR
07/24/19
NO CHANGE
Target $50
PIPR
Overweight
Boston Scientific second half guidance achievable, says Piper Jaffray
Boston Scientific's Q2 results were essentially in line with consensus estimates as "some concerning areas" from Q1 persisted, such as Neuromod, but were offset by faster growth areas like Medsurg and Structural Heart, Piper Jaffray analyst Matt O'Brien tells investors in a research note. The second half of 2019 acceleration in the core business, implied by the unchanged guidance, is achievable, says the analyst. He reiterates an Overweight rating on Boston Scientific shares with a $50 price target.
08/07/19
PIPR
08/07/19
NO CHANGE
PIPR
Piper says FDA update on paclitaxel-coated devices 'likely keeps the status quo'
After the FDA issued an update on its analysis of a late mortality signal in patients treated for peripheral artery disease in the femoropopliteal artery with paclitaxel-coated balloons and paclitaxel-eluting stents, Piper Jaffray analyst Matt O'Brien said the FDA's conclusion "likely keeps the status quo as far as usage in 2019." However, he still sees a significant patency benefit with these devices and expects further clinical data to resolve doctor's concerns in the longer-term, O'Brien stated. Makers of paclitaxel-coated devices include Boston Scientific (BSX) and Medtronic (MDT).

TODAY'S FREE FLY STORIES

HUMRF

Hummingbird

$0.00

(0.00%)

06:21
09/20/19
09/20
06:21
09/20/19
06:21
Initiation
Hummingbird initiated  »

Hummingbird initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XENE

Xenon Pharmaceuticals

$9.30

-0.01 (-0.11%)

06:21
09/20/19
09/20
06:21
09/20/19
06:21
Initiation
Xenon Pharmaceuticals initiated  »

Xenon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

ADDYY

Adidas

$0.00

(0.00%)

06:20
09/20/19
09/20
06:20
09/20/19
06:20
Initiation
Adidas initiated  »

Adidas initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$128.67

-3.065 (-2.33%)

06:20
09/20/19
09/20
06:20
09/20/19
06:20
Initiation
Berenberg starts Wayfair with Sell rating on intensifying competition »

Berenberg analyst Graham…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SQ

Square

$59.08

-0.63 (-1.06%)

06:20
09/20/19
09/20
06:20
09/20/19
06:20
Recommendations
Square analyst commentary  »

Square price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Oct

  • 06

    Nov

FB

Facebook

$190.15

1.96 (1.04%)

06:19
09/20/19
09/20
06:19
09/20/19
06:19
Periodicals
Zuckerberg meets with Trump with Facebook on the defense, Bloomberg says »

Naomi Nix, Rebecca Kern,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 24

    Sep

  • 27

    Oct

ATO

Atmos Energy

$112.30

0.49 (0.44%)

06:18
09/20/19
09/20
06:18
09/20/19
06:18
Initiation
Atmos Energy initiated  »

Atmos Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FE

FirstEnergy

$48.10

0.01 (0.02%)

06:17
09/20/19
09/20
06:17
09/20/19
06:17
Downgrade
FirstEnergy rating change  »

FirstEnergy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

  • 10

    Nov

NFLX

Netflix

$286.58

-4.97 (-1.70%)

06:17
09/20/19
09/20
06:17
09/20/19
06:17
Periodicals
Netflix CEO plans to make 'big increase' in buying U.K. content, Reuters reports »

Netflix plans to make a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 16

    Oct

GL

Globe Life

$94.34

-0.59 (-0.62%)

06:15
09/20/19
09/20
06:15
09/20/19
06:15
Initiation
Globe Life initiated  »

Globe Life initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$220.91

-1.8 (-0.81%)

06:14
09/20/19
09/20
06:14
09/20/19
06:14
Recommendations
Apple analyst commentary  »

Apple's new iPhone…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERIC

Ericsson

$8.19

0.04 (0.49%)

06:12
09/20/19
09/20
06:12
09/20/19
06:12
Upgrade
Ericsson rating change  »

Ericsson upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

STX

Seagate

$52.85

-3.89 (-6.86%)

06:12
09/20/19
09/20
06:12
09/20/19
06:12
Recommendations
Seagate analyst commentary  »

Seagate price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$51.58

-0.15 (-0.29%)

06:12
09/20/19
09/20
06:12
09/20/19
06:12
Periodicals
Intel increasing EUV equipment, material purchases, DigiTimes reports »

Intel has started placing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

AMZN

Amazon.com

$1,822.21

4.21 (0.23%)

06:10
09/20/19
09/20
06:10
09/20/19
06:10
Periodicals
Amazon CEO announces goal to be carbon neutral by 2040, CNBC reports »

Amazon CEO Jeff Bezos has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Oct

RAMP

LiveRamp

$46.44

0.43 (0.93%)

06:10
09/20/19
09/20
06:10
09/20/19
06:10
Upgrade
LiveRamp rating change  »

LiveRamp upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCP

TC PipeLines

06:07
09/20/19
09/20
06:07
09/20/19
06:07
Upgrade
TC PipeLines rating change  »

TC PipeLines upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPAM

Epam Systems

$185.46

0.86 (0.47%)

06:07
09/20/19
09/20
06:07
09/20/19
06:07
Initiation
Epam Systems initiated  »

Epam Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$190.15

1.96 (1.04%)

06:06
09/20/19
09/20
06:06
09/20/19
06:06
Periodicals
Person dies by suicide at Facebook headquarters in Menlo Park, BI reports »

A Facebook employee has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 24

    Sep

  • 27

    Oct

CTSH

Cognizant

$63.44

-0.07 (-0.11%)

06:06
09/20/19
09/20
06:06
09/20/19
06:06
Initiation
Cognizant initiated  »

Cognizant initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$190.15

1.96 (1.04%)

06:05
09/20/19
09/20
06:05
09/20/19
06:05
Hot Stocks
Trump says 'nice meeting with' Facebook CEO Mark Zuckerberg »

President Donald Trump…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 24

    Sep

  • 27

    Oct

XLNX

Xilinx

$103.59

-1.3 (-1.24%)

06:04
09/20/19
09/20
06:04
09/20/19
06:04
Downgrade
Xilinx rating change  »

Xilinx downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

SAIC

SAIC

$83.88

-0.46 (-0.55%)

06:03
09/20/19
09/20
06:03
09/20/19
06:03
Initiation
SAIC initiated  »

SAIC initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LDOS

Leidos

$87.37

-0.21 (-0.24%)

06:02
09/20/19
09/20
06:02
09/20/19
06:02
Initiation
Leidos initiated  »

Leidos initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CACI

CACI

$224.49

-1.76 (-0.78%)

06:01
09/20/19
09/20
06:01
09/20/19
06:01
Initiation
CACI initiated  »

CACI initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.